melasma
(2)
AVAVA, Inc.
AVAVA, Inc. is a Waltham, Massachusetts medical aesthetics company that builds energy-based laser platforms for skin renewal that work across all skin tones. Spun out of Boston-based Blossom Innovations and rooted in research from Massachusetts General Hospital's Wellman Center for Photomedicine, AVAVA's flagship MIRIA Skin Treatment System pairs patented Focal Point Technology with AI-driven skin visualization to deliver precise, high-energy intradermal treatment for conditions like melasma, hyperpigmentation, and acne scars with minimal downtime.
DermBiont, Inc.
DermBiont is a Boston-based, clinical-stage biotechnology company developing first-in-class targeted topical therapeutics that treat the root cause of common skin diseases. Its lead programs are SM-020, a topical AKT kinase inhibitor for seborrheic keratoses, and SM-030, a topical PKC-beta inhibitor for melasma and other hyperpigmentation disorders, with earlier-stage work aimed at basal cell carcinoma and Gorlin syndrome. Founded in 2017 by dermatology-drug veteran Karl Beutner, the company has raised roughly $79M-plus across multiple rounds, including a $35.2M Series B led by Double Point Ventures in 2023.